Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Agulnik

Showing results (21-30 of 112) with videos related to

Pageof 12
Sort By:
Cancers|April 27, 2024
Prices and Trends in FDA-Approved Medications for SarcomasCaleb Hwang, Mark Agulnik, Brian Schulte
Oncology (Williston Park, N.Y.)|April 16, 2008
New therapeutic options in gastrointestinal stromal tumorsEytan Stein, Olivia Aranha, Mark Agulnik
Expert Review of Clinical Pharmacology|April 28, 2017
Olaratumab for advanced soft tissue sarcomaAlexander Tobias, Michael P O'brien, Mark Agulnik
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2011
Management of neuroendocrine tumors of unknown originAriel Polish, Maxwell T Vergo, Mark Agulnik
Oncotargets and Therapy|March 16, 2013
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLCValerie Nelson, Jacqueline Ziehr, Mark Agulnik, et al.
Drugs|April 7, 2017
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and ImmunotherapiesJonathan Moreira, Alexander Tobias, Michael P O'Brien, et al.
Frontiers in Oncology|August 2, 2021
The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck CancerRebecca R Pharaon, Yan Xing, Mark Agulnik, et al.
International Journal of Clinical Oncology|March 12, 2010
Treatment of multiple keratoacanthomas with erlotinibDavid C Reid, Joan Guitart, Mark Agulnik, et al.
Expert Review of Anticancer Therapy|January 20, 2026
Management of tenosynovial giant cell tumor: approved and investigational therapiesAlexander P Conway, Andrew Lim, Brian C Schulte, et al.
Chemotherapy|March 15, 2012
Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinibJana Svetlichnaya, Timothy K Huyck, Jeffrey D Wayne, et al.
Pageof 12

Showing results (21-30 of 112) with videos related to

Sort By:
Pageof 12
Cancers|April 27, 2024
Prices and Trends in FDA-Approved Medications for SarcomasCaleb Hwang, Mark Agulnik, Brian Schulte
Oncology (Williston Park, N.Y.)|April 16, 2008
New therapeutic options in gastrointestinal stromal tumorsEytan Stein, Olivia Aranha, Mark Agulnik
Expert Review of Clinical Pharmacology|April 28, 2017
Olaratumab for advanced soft tissue sarcomaAlexander Tobias, Michael P O'brien, Mark Agulnik
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2011
Management of neuroendocrine tumors of unknown originAriel Polish, Maxwell T Vergo, Mark Agulnik
Oncotargets and Therapy|March 16, 2013
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLCValerie Nelson, Jacqueline Ziehr, Mark Agulnik, et al.
Drugs|April 7, 2017
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and ImmunotherapiesJonathan Moreira, Alexander Tobias, Michael P O'Brien, et al.
Frontiers in Oncology|August 2, 2021
The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck CancerRebecca R Pharaon, Yan Xing, Mark Agulnik, et al.
International Journal of Clinical Oncology|March 12, 2010
Treatment of multiple keratoacanthomas with erlotinibDavid C Reid, Joan Guitart, Mark Agulnik, et al.
Expert Review of Anticancer Therapy|January 20, 2026
Management of tenosynovial giant cell tumor: approved and investigational therapiesAlexander P Conway, Andrew Lim, Brian C Schulte, et al.
Chemotherapy|March 15, 2012
Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinibJana Svetlichnaya, Timothy K Huyck, Jeffrey D Wayne, et al.
Pageof 12